Cumulative incidence

Dengue fever

Serostatus

Cohort

Dengue virus

Proportional hazards model

Virology

Viral load

Immunology

Physics

Optics

Vaccination

Human immunodeficiency virus (HIV)

Dengue vaccine

Internal medicine

Confidence interval

Hazard ratio

Medicine

Incidence (geometry)

Vaccine efficacy

New England Journal of Medicine

In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti–nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy.

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy